Reviewing CellaVision AB (publ) (OTCMKTS:CLVSF) and Lucid Diagnostics (NASDAQ:LUCD)

CellaVision AB (publ) (OTCMKTS:CLVSFGet Free Report) and Lucid Diagnostics (NASDAQ:LUCDGet Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Profitability

This table compares CellaVision AB (publ) and Lucid Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CellaVision AB (publ) N/A N/A N/A
Lucid Diagnostics -2,169.07% -8,334.14% -121.11%

Insider & Institutional Ownership

3.0% of CellaVision AB (publ) shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 4.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares CellaVision AB (publ) and Lucid Diagnostics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CellaVision AB (publ) N/A N/A N/A N/A N/A
Lucid Diagnostics $2.43 million 16.08 -$56.17 million ($1.27) -0.64

CellaVision AB (publ) has higher earnings, but lower revenue than Lucid Diagnostics.

Analyst Ratings

This is a breakdown of recent ratings for CellaVision AB (publ) and Lucid Diagnostics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CellaVision AB (publ) 0 0 1 0 3.00
Lucid Diagnostics 0 0 2 0 3.00

Lucid Diagnostics has a consensus target price of $2.75, indicating a potential upside of 239.55%. Given Lucid Diagnostics’ higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than CellaVision AB (publ).

Summary

Lucid Diagnostics beats CellaVision AB (publ) on 5 of the 8 factors compared between the two stocks.

About CellaVision AB (publ)

(Get Free Report)

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. Further, it offers reagents to identify cell and tissue morphology, parasites, and bacteria in diagnosing various diseases; and instruments, including RAL SmearBox, RAL Stainbox, and RAL Stainer. The company sells its products to hospital and commercial laboratories. The company was incorporated in 1994 and is headquartered in Lund, Sweden.

About Lucid Diagnostics

(Get Free Report)

Lucid Diagnostics Inc., a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Receive News & Ratings for CellaVision AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CellaVision AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.